Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12349326 | 0.95 | KDM4E (0.33) | KDM4EATML3MBTL1LMNATP53 | |
| SCHEMBL12349318 | 0.93 | KDM4E (0.40) | KDM4EATML3MBTL1LMNATP53 | |
| SCHEMBL12349332 | 0.87 | KDM4E (0.39) | KDM4EATML3MBTL1ALDH1A1RXFP1 | |
| SCHEMBL12349325 | 0.82 | KDM4E (0.36) | KDM4EATML3MBTL1ALDH1A1RXFP1 | |
| SCHEMBL12349317 | 0.81 | KDM4E (0.42) | KDM4EATML3MBTL1LMNATP53 | |
| SCHEMBL12349296 | 0.80 | RXFP1 (0.41) | LMNATP53POLBMAPTRXFP1 | |
| SCHEMBL5405221 | 0.77 | KDM4E (0.59) | KDM4EATML3MBTL1LMNAPOLB | |
| SCHEMBL12108646 | 0.76 | KDM4E (0.52) | KDM4EATML3MBTL1LMNAPOLB | |
| SCHEMBL12190855 | 0.74 | RXFP1 (0.48) | LMNATP53POLBMAPTRXFP1 | |
| SCHEMBL20710280 | 0.73 | KDM4E (0.41) | KDM4EATML3MBTL1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989091-B2 | Silanes containing phenothiazine-S-oxide or phenothiazine-S,S-dioxide groups and the use thereof in OLEDs | BASF SE (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20100187980-A1 | SILANES CONTAINING PHENOTHIAZINE-S-OXIDE OR PHENOTHIAZINE-S,S-DIOXIDE GROUPS AND THE USE THEREOF IN OLEDS | BASF SE (DE) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100187980-A1 | SILANES CONTAINING PHENOTHIAZINE-S-OXIDE OR PHENOTHIAZINE-S,S-DIOXIDE GROUPS AND THE USE THEREOF IN OLEDS | OPRD1, PPID, PLOD2 | KDM4E 2722/4885ATM 4166/4885L3MBTL1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.